Literature DB >> 23071276

IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions.

Piers E M Patten1, Charles C Chu, Emilia Albesiano, Rajendra N Damle, Xiao-Jie Yan, Dorothy Kim, Lu Zhang, Amanda R Magli, Jacqueline Barrientos, Jonathan E Kolitz, Steven L Allen, Kanti R Rai, Sergio Roa, Patricia K Mongini, Thomas MacCarthy, Matthew D Scharff, Nicholas Chiorazzi.   

Abstract

Clonal evolution occurs during the course of chronic lymphocytic leukemia (CLL) and activation-induced deaminase (AID) could influence this process. However, this possibility has been questioned in CLL because the number of circulating AID mRNA(+) cells is exceedingly low; synthesis of AID protein by blood CLL cells has not been demonstrated; the full range of AID functions is lacking in unmutated CLL (U-CLL), and no prospective analysis linking AID expression and disease severity has been reported. The results of the present study show that circulating CLL cells and those within secondary lymphoid tissues can make AID mRNA and protein. This production is related to cell division because more AID mRNA was detected in recently divided cells and AID protein was limited to the dividing fraction and was up-regulated on induction of cell division. AID protein was functional because AID(+) dividing cells exhibited more double-stranded DNA breaks, IGH class switching, and new IGHV-D-J mutations. Each of these actions was documented in U-CLL and mutated CLL (M-CLL). Furthermore, AID protein was associated with worse patient outcome and adverse cytogenetics. We conclude that the production of fully functional AID protein by U-CLL and M-CLL cells could be involved in clonal evolution of the disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23071276      PMCID: PMC3520620          DOI: 10.1182/blood-2012-08-449744

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia.

Authors:  Helen McCarthy; William G Wierda; Lynn L Barron; Candy C Cromwell; Jing Wang; Kevin R Coombes; Roberto Rangel; Kojo S J Elenitoba-Johnson; Michael J Keating; Lynne V Abruzzo
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

2.  Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone.

Authors:  Emilia Albesiano; Bradley T Messmer; Rajendra N Damle; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

3.  Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia B cells.

Authors:  Andrea Cerutti; Hong Zan; Edmund C Kim; Shefali Shah; Elaine J Schattner; András Schaffer; Paolo Casali
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

4.  Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1.

Authors:  Satomi Ito; Hitoshi Nagaoka; Reiko Shinkura; Nasim Begum; Masamichi Muramatsu; Mikiyo Nakata; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

5.  High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia.

Authors:  D Heintel; E Kroemer; D Kienle; I Schwarzinger; A Gleiss; J Schwarzmeier; R Marculescu; T Le; C Mannhalter; A Gaiger; S Stilgenbauer; H Döhner; C Fonatsch; U Jäger
Journal:  Leukemia       Date:  2004-04       Impact factor: 11.528

6.  Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation.

Authors:  Pablo Oppezzo; Françoise Vuillier; Yuri Vasconcelos; Gérard Dumas; Christian Magnac; Beatrice Payelle-Brogard; Otto Pritsch; Guillaume Dighiero
Journal:  Blood       Date:  2003-01-09       Impact factor: 22.113

7.  The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process.

Authors:  Bradley T Messmer; Emilia Albesiano; Davorka Messmer; Nicholas Chiorazzi
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

8.  Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia.

Authors:  Z M Sthoeger; M Wakai; D B Tse; V P Vinciguerra; S L Allen; D R Budman; S M Lichtman; P Schulman; L R Weiselberg; N Chiorazzi
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

9.  Chronic lymphocytic leukemia B cells can undergo somatic hypermutation and intraclonal immunoglobulin V(H)DJ(H) gene diversification.

Authors:  Carmela Gurrieri; Peter McGuire; Hong Zan; Xiao-Jie Yan; Andrea Cerutti; Emilia Albesiano; Steven L Allen; Vincent Vinciguerra; Kanti R Rai; Manlio Ferrarini; Paolo Casali; Nicholas Chiorazzi
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

10.  Somatic hypermutation is limited by CRM1-dependent nuclear export of activation-induced deaminase.

Authors:  Kevin M McBride; Vasco Barreto; Almudena R Ramiro; Pete Stavropoulos; Michel C Nussenzweig
Journal:  J Exp Med       Date:  2004-04-26       Impact factor: 14.307

View more
  29 in total

1.  Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process.

Authors:  Piers E M Patten; Gerardo Ferrer; Shih-Shih Chen; Rita Simone; Sonia Marsilio; Xiao-Jie Yan; Zachary Gitto; Chaohui Yuan; Jonathan E Kolitz; Jacqueline Barrientos; Steven L Allen; Kanti R Rai; Thomas MacCarthy; Charles C Chu; Nicholas Chiorazzi
Journal:  JCI Insight       Date:  2016-04-07

2.  TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.

Authors:  Patricia K A Mongini; Rashmi Gupta; Erin Boyle; Jennifer Nieto; Hyunjoo Lee; Joanna Stein; Jela Bandovic; Tatjana Stankovic; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

3.  Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins.

Authors:  Rashmi Gupta; Wentian Li; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2019-04-15       Impact factor: 5.422

4.  HSP90 inhibitors decrease AID levels and activity in mice and in human cells.

Authors:  Damien Montamat-Sicotte; Ludivine C Litzler; Cecilia Abreu; Shiva Safavi; Astrid Zahn; Alexandre Orthwein; Markus Müschen; Pablo Oppezzo; Denise P Muñoz; Javier M Di Noia
Journal:  Eur J Immunol       Date:  2015-05-18       Impact factor: 5.532

5.  Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling.

Authors:  Shih-Shih Chen; Franak Batliwalla; Nichol E Holodick; Xiao-Jie Yan; Sophia Yancopoulos; Carlo M Croce; Thomas L Rothstein; Nicholas Chiorazzi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-02       Impact factor: 11.205

Review 6.  Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?

Authors:  Ricardo García-Muñoz; Luis Llorente
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

7.  Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.

Authors:  Sara S Alhakeem; Mary K McKenna; Karine Z Oben; Sunil K Noothi; Jacqueline R Rivas; Gerhard C Hildebrandt; Roger A Fleischman; Vivek M Rangnekar; Natarajan Muthusamy; Subbarao Bondada
Journal:  J Immunol       Date:  2018-04-30       Impact factor: 5.422

8.  Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCα subversion induces up-regulation of PKCβII expression in B lymphocytes.

Authors:  Rinako Nakagawa; Milica Vukovic; Anuradha Tarafdar; Emilio Cosimo; Karen Dunn; Alison M McCaig; Ailsa Holroyd; Fabienne McClanahan; Alan G Ramsay; John G Gribben; Alison M Michie
Journal:  Haematologica       Date:  2015-01-23       Impact factor: 9.941

9.  Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia.

Authors:  Kristina Zaprazna; Kamila Reblova; Veronika Svobodova; Lenka Radova; Vojtech Bystry; Jiri Baloun; Kristina Durechova; Nikola Tom; Tomas Loja; Martina Buresova; Kamila Stranska; Alexandra Oltova; Michael Doubek; Michael L Atchison; Martin Trbusek; Jitka Malcikova; Sarka Pospisilova
Journal:  Ann Hematol       Date:  2018-10-27       Impact factor: 3.673

10.  AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL.

Authors:  Maria Schubert; Franz Josef Gassner; Michael Huemer; Jan Philip Höpner; Ekaterina Akimova; Markus Steiner; Alexander Egle; Richard Greil; Nadja Zaborsky; Roland Geisberger
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.